| Helmut O Steinberg, MD | |
|
975 W Walnut St, Ib 424, Indianapolis, IN 46202-5181 | |
| (317) 274-3960 | |
| Not Available |
| Full Name | Helmut O Steinberg |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 37 Years |
| Location | 975 W Walnut St, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467417246 | NPI | - | NPPES |
| 100099760 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 01044306 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Healthcare Memphis Hospitals | Memphis, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ut Medical Group, Inc. | 3173435369 | 82 |
News Archive
The abuse of methamphetamine - a powerful and highly addictive psychostimulant that is toxic to the nervous system - has reached epidemic proportions in many parts of the United States. The National Institute on Drug Abuse estimates that more than 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.
Deep brain stimulation has been used to treat Parkinson's disease symptoms for 25 years, but limitations have led researchers to look for ways to improve the technique.
Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.
A Simon Fraser University researcher is among four scientists who argue that cholesterol may slow or stop cancer cell growth. They describe how cholesterol-binding proteins called ORPs may control cell growth in A Detour for Yeast Oxysterol Binding Proteins, a paper published in the latest issue of the Journal of Biological Chemistry.
IOS Press announces publication of a special issue of NeuroRehabilitation: An International Journal devoted specifically to hypoxic-ischemic brain injury (HI-BI), a significant disruption of brain function due to a deficient supply of oxygen to the brain.
› Verified 7 days ago
| Entity Name | Ut Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780676650 PECOS PAC ID: 3173435369 Enrollment ID: O20031105000384 |
News Archive
The abuse of methamphetamine - a powerful and highly addictive psychostimulant that is toxic to the nervous system - has reached epidemic proportions in many parts of the United States. The National Institute on Drug Abuse estimates that more than 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.
Deep brain stimulation has been used to treat Parkinson's disease symptoms for 25 years, but limitations have led researchers to look for ways to improve the technique.
Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.
A Simon Fraser University researcher is among four scientists who argue that cholesterol may slow or stop cancer cell growth. They describe how cholesterol-binding proteins called ORPs may control cell growth in A Detour for Yeast Oxysterol Binding Proteins, a paper published in the latest issue of the Journal of Biological Chemistry.
IOS Press announces publication of a special issue of NeuroRehabilitation: An International Journal devoted specifically to hypoxic-ischemic brain injury (HI-BI), a significant disruption of brain function due to a deficient supply of oxygen to the brain.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Helmut O Steinberg, MD 550 N Meridian St, Ste 114, Indianapolis, IN 46204-1207 Ph: () - | Helmut O Steinberg, MD 975 W Walnut St, Ib 424, Indianapolis, IN 46202-5181 Ph: (317) 274-3960 |
News Archive
The abuse of methamphetamine - a powerful and highly addictive psychostimulant that is toxic to the nervous system - has reached epidemic proportions in many parts of the United States. The National Institute on Drug Abuse estimates that more than 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.
Deep brain stimulation has been used to treat Parkinson's disease symptoms for 25 years, but limitations have led researchers to look for ways to improve the technique.
Alkermes plc today announced the initiation of a phase 3 clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070, a proprietary Alkermes molecule, is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system disorders.
A Simon Fraser University researcher is among four scientists who argue that cholesterol may slow or stop cancer cell growth. They describe how cholesterol-binding proteins called ORPs may control cell growth in A Detour for Yeast Oxysterol Binding Proteins, a paper published in the latest issue of the Journal of Biological Chemistry.
IOS Press announces publication of a special issue of NeuroRehabilitation: An International Journal devoted specifically to hypoxic-ischemic brain injury (HI-BI), a significant disruption of brain function due to a deficient supply of oxygen to the brain.
› Verified 7 days ago
Irene A Carrothers, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1701 Senate Blvd, Indianapolis, IN 46202 Phone: 317-963-8776 Fax: 317-963-5285 | |
Liam P Howley, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1001 West 10th St Opw-m200, Indiana University Department Of Medicine, Indianapolis, IN 46202 Phone: 317-630-6560 | |
Cristina Nancy Perez Chumbiauca, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 550 University Blvd, Indianapolis, IN 46202 Phone: 317-944-5000 | |
Dr. Andrew Jonathen Ortega, DO Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 702 Rotary Cir, Indianapolis, IN 46202 Phone: 317-278-4427 | |
Lawrence John Born, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 8424 Naab Rd, #3-j, Indianapolis, IN 46260 Phone: 317-872-7396 Fax: 317-879-8328 | |
Brian T Robinson, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1001 W 10th St, Indianapolis, IN 46202 Phone: 317-630-7979 Fax: 317-630-2668 | |
Steven T Hugenberg, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 550 University Blvd, Indianapolis, IN 46202 Phone: 317-944-8660 |